1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS)

M. Ingham; Jean Yves Blay; J. Baird; Dhiren D’Silva; K. O'Keefe; R. Kong; R. Spiegel; M. Wahba; M. Weetall

doi:10.1016/j.annonc.2022.07.1917

Related publications

Article2012

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet

Journal of Hepatology

Article2020

Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Ellen B. Gurary, Abby B. Siegel, Lokesh Jain, Ann‐Lii Cheng, Andrew X. Zhu

Article2022

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu

Article2017

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

Masatoshi Kudo, Yoon‐Koo Kang, Joong‐Won Park, Shukui Qin, Yoshitaka Inaba, Éric Assenat, Yoshiko Umeyama, María José Lechuga, Olga Valota, Yosuke Fujii, Jean‐François Martini, James A. Williams, Shuntaro Obi

Article2025

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma

Gregory M. Coté, Sant P. Chawla, George D. Demetri, Bernd Kasper, Robin L. Jones, Javier Martín‐Broto, Joseph Wooley, Mia C. Weiss, Salvatore Tafuto, Giuseppe Badalamenti, Irene Carrasco, Paloma Peinado, Jean Yves Blay, Gastón Boggio, Cristian Fernández, Antonio Nieto, Carmen Kahatt, Vicente Alfaro, Axel Le Cesne